503 related articles for article (PubMed ID: 22796657)
1. The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat.
Bishnoi HK; Mahadevan N; Balakumar P
Pharmacol Res; 2012 Oct; 66(4):349-56. PubMed ID: 22796657
[TBL] [Abstract][Full Text] [Related]
2. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
Arora MK; Reddy K; Balakumar P
Eur J Pharmacol; 2010 Jun; 636(1-3):137-44. PubMed ID: 20347778
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy.
Kadian S; Mahadevan N; Balakumar P
Eur J Pharmacol; 2013 Jan; 698(1-3):388-96. PubMed ID: 23085026
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats.
Balakumar P; Varatharajan R; Nyo YH; Renushia R; Raaginey D; Oh AN; Akhtar SS; Rupeshkumar M; Sundram K; Dhanaraj SA
Pharmacol Res; 2014 Dec; 90():36-47. PubMed ID: 25263930
[TBL] [Abstract][Full Text] [Related]
5. Role of fenofibrate alone and in combination with telmisartan on renal ischemia/reperfusion injury.
Bhalodia Y; Sheth N; Vaghasiya J; Jivani N
Ren Fail; 2010; 32(9):1088-94. PubMed ID: 20863214
[TBL] [Abstract][Full Text] [Related]
6. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat.
Balakumar P; Chakkarwar VA; Singh M
Mol Cell Biochem; 2009 Jan; 320(1-2):149-62. PubMed ID: 18830571
[TBL] [Abstract][Full Text] [Related]
7. Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?
Balakumar P; Kadian S; Mahadevan N
Pharmacol Res; 2012 Apr; 65(4):430-6. PubMed ID: 22285932
[TBL] [Abstract][Full Text] [Related]
8. Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
Sharma AK; Kanawat DS; Mishra A; Dhakad PK; Sharma P; Srivastava V; Joshi S; Joshi M; Raikwar SK; Kurmi MK; Srinivasan BP
J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):410-8. PubMed ID: 23396552
[TBL] [Abstract][Full Text] [Related]
9. Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy.
Mulay SR; Gaikwad AB; Tikoo K
Chem Biol Interact; 2010 Apr; 185(2):137-42. PubMed ID: 20223228
[TBL] [Abstract][Full Text] [Related]
10. Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model.
El-Mahdy NA; El-Sayad ME; El-Kadem AH
Biomed Pharmacother; 2016 Jul; 81():136-144. PubMed ID: 27261587
[TBL] [Abstract][Full Text] [Related]
11. Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats.
Tawfik MK
Eur Rev Med Pharmacol Sci; 2012 May; 16(5):600-9. PubMed ID: 22774400
[TBL] [Abstract][Full Text] [Related]
12. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
Ge J; Miao JJ; Sun XY; Yu JY
J Ethnopharmacol; 2016 Aug; 189():238-49. PubMed ID: 27224243
[TBL] [Abstract][Full Text] [Related]
13. Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy.
Yaribeygi H; Mohammadi MT; Rezaee R; Sahebkar A
J Cell Biochem; 2018 Sep; 119(9):7458-7469. PubMed ID: 29761900
[TBL] [Abstract][Full Text] [Related]
14. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
[TBL] [Abstract][Full Text] [Related]
15. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
Anjaneyulu M; Chopra K
Am J Nephrol; 2004; 24(5):488-96. PubMed ID: 15353911
[TBL] [Abstract][Full Text] [Related]
16. Renoprotective Effects of Fenofibrate via Modulation of LKB1/AMPK mRNA Expression and Endothelial Dysfunction in a Rat Model of Diabetic Nephropathy.
Al-Rasheed NM; Al-Rasheed NM; Attia HA; Al-Amin MA; Al-Ajmi HN; Hasan IH; Mohamad RA; Sinjilawi NA
Pharmacology; 2015; 95(5-6):229-39. PubMed ID: 25967095
[TBL] [Abstract][Full Text] [Related]
17. Flavonoid rich fraction of Punica granatum improves early diabetic nephropathy by ameliorating proteinuria and disturbed glucose homeostasis in experimental animals.
Ankita P; Deepti B; Nilam M
Pharm Biol; 2015 Jan; 53(1):61-71. PubMed ID: 25289530
[TBL] [Abstract][Full Text] [Related]
18. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
[TBL] [Abstract][Full Text] [Related]
19. Nephroprotective effect of Combretum micranthum G. Don in nicotinamide-streptozotocin induced diabetic nephropathy in rats: In-vivo and in-silico experiments.
Kpemissi M; Potârniche AV; Lawson-Evi P; Metowogo K; Melila M; Dramane P; Taulescu M; Chandramohan V; Suhas DS; Puneeth TA; S VK; Vlase L; Andrei S; Eklu-Gadegbeku K; Sevastre B; Veerapur VP
J Ethnopharmacol; 2020 Oct; 261():113133. PubMed ID: 32673708
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
Hofni A; El-Moselhy MA; Taye A; Khalifa MM
Eur J Pharmacol; 2014 Dec; 744():173-82. PubMed ID: 25446917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
